Source: News Max Author: By Brian Trusdell Photo: Getty

The anti-malarial drug promoted by the US President as a treatment for COVID-19 — and derided by his critics — has been found to help outpatients with the disease, a new peer-reviewed study says.

Only 3% of patients that took hydroxychloroquine along with zinc and the antibiotic azithromycin were hospitalized compared to 15% who did not take it, according to the study published in the International Journal of Antimicrobial Agents.

The study comes following a summer of rancor over the drug. Trump hailed it a potential cure and said this spring he was taking it as a prophylactic, or preventive, medicine.

Others, including “Hawaii 5-0” actor Daniel Dae Kim and Michigan state legislator Rep. Karen Whitsett, hailed the drug as saving their lives.

The British medical journal The Lancet published a story saying the drug was potentially toxic, then withdrew it because the data was fraudulent.

Advocates for hydroxychloroquine claim it might not be effective for patients already hospitalized, but those with milder symptoms could benefit, the Washington Examiner reported.

Related: COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study

Hydroxychloroquine cocktail saves lives of high-risk Covid-19 patients

HCQ is effective for COVID-19 when used early: analysis of 132 studies

Hydroxychloroquine Not Linked to Longer Heart Rhythm Intervals in Rheumatoid Arthritis or Lupus Patients

India: Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »